Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509149716> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2509149716 endingPage "57" @default.
- W2509149716 startingPage "51" @default.
- W2509149716 abstract "Biochemical properties of Factor VIII (FVIII) in highly-purified FVIII concentrates (CROSS EIGHT M) produced by monoclonal antibody column were studied and compared with those of Hemofil M which was already used clinically. The FVIII clotting activity (FVIII:Cclot) levels obtained by one-stage method using severe hemophilia A plasma as a substrate were 614-729U/vial and identical with those indicated on the label (500U/vial). The FVIII light chain antigen (FVIIIL:Ag) levels measured by Enzyme Immunoassay were 540-760U/vial. The ratio of FVIIIL:Ag to FVIII:Cclot (FVIIIL:Ag/FVIII:Cclot) were 0.88-1.04. The ratio of FVIIIL:Ag to von Willebrand Factor antigen (vWF:Ag) (FVIIIL:Ag/vWF:Ag) were 49.0-60.8. No difference was observed between CROSS EIGHT M and Hemofil M on the FVIII:Cclot levels, FVIIIL:Ag levels, FVIIIL:Ag/FVIII:Cclot and FVIIIL:Ag/vWF:Ag.SDS-PAGE patterns showed almost no contamination except albumin being added as a stabilizer. Western blot analysis revealed FVIII heavy chain antigen of M. W. 90kDa-220kDa and FVIII light chain antigen of M. W. 80kDa. No degradates of MW. 43kDa-50kDa derived from FVIII heavy chain antigen were observed. CROSS EIGHT M lacked the large multimers of vWF which were detected in normal human pooled plasma. No difference was observed between CROSS EIGHT M and Hemofil M by western blot analysis of FVIII and multimer analysis of vWF.These results suggest that CROSS EIGHT M preserves the fundamental structure of FVIII molecule for coagulant activity. Therefore, CROSS EIGHT M as well as Hemofil M may be clinically used with safety as FVIII concentrates." @default.
- W2509149716 created "2016-09-16" @default.
- W2509149716 creator A5007565958 @default.
- W2509149716 creator A5022567912 @default.
- W2509149716 creator A5032129822 @default.
- W2509149716 creator A5053866517 @default.
- W2509149716 creator A5054908522 @default.
- W2509149716 creator A5057970590 @default.
- W2509149716 creator A5081556786 @default.
- W2509149716 creator A5086471920 @default.
- W2509149716 date "1992-01-01" @default.
- W2509149716 modified "2023-09-26" @default.
- W2509149716 title "Biochemical properties of factor VIII in highly-purified factor VIII concentrates (cross eight M) produced by monoclonal antibody column." @default.
- W2509149716 cites W1489283767 @default.
- W2509149716 cites W1880892278 @default.
- W2509149716 cites W2061798383 @default.
- W2509149716 cites W2065336178 @default.
- W2509149716 cites W2100837269 @default.
- W2509149716 cites W2462867594 @default.
- W2509149716 doi "https://doi.org/10.3925/jjtc1958.38.51" @default.
- W2509149716 hasPublicationYear "1992" @default.
- W2509149716 type Work @default.
- W2509149716 sameAs 2509149716 @default.
- W2509149716 citedByCount "0" @default.
- W2509149716 crossrefType "journal-article" @default.
- W2509149716 hasAuthorship W2509149716A5007565958 @default.
- W2509149716 hasAuthorship W2509149716A5022567912 @default.
- W2509149716 hasAuthorship W2509149716A5032129822 @default.
- W2509149716 hasAuthorship W2509149716A5053866517 @default.
- W2509149716 hasAuthorship W2509149716A5054908522 @default.
- W2509149716 hasAuthorship W2509149716A5057970590 @default.
- W2509149716 hasAuthorship W2509149716A5081556786 @default.
- W2509149716 hasAuthorship W2509149716A5086471920 @default.
- W2509149716 hasBestOaLocation W25091497161 @default.
- W2509149716 hasConcept C104317684 @default.
- W2509149716 hasConcept C147483822 @default.
- W2509149716 hasConcept C153911025 @default.
- W2509149716 hasConcept C159654299 @default.
- W2509149716 hasConcept C185592680 @default.
- W2509149716 hasConcept C203014093 @default.
- W2509149716 hasConcept C2776415932 @default.
- W2509149716 hasConcept C2779394231 @default.
- W2509149716 hasConcept C2780420688 @default.
- W2509149716 hasConcept C36394416 @default.
- W2509149716 hasConcept C43617362 @default.
- W2509149716 hasConcept C542903549 @default.
- W2509149716 hasConcept C55493867 @default.
- W2509149716 hasConcept C71924100 @default.
- W2509149716 hasConcept C72092618 @default.
- W2509149716 hasConcept C86803240 @default.
- W2509149716 hasConcept C89560881 @default.
- W2509149716 hasConceptScore W2509149716C104317684 @default.
- W2509149716 hasConceptScore W2509149716C147483822 @default.
- W2509149716 hasConceptScore W2509149716C153911025 @default.
- W2509149716 hasConceptScore W2509149716C159654299 @default.
- W2509149716 hasConceptScore W2509149716C185592680 @default.
- W2509149716 hasConceptScore W2509149716C203014093 @default.
- W2509149716 hasConceptScore W2509149716C2776415932 @default.
- W2509149716 hasConceptScore W2509149716C2779394231 @default.
- W2509149716 hasConceptScore W2509149716C2780420688 @default.
- W2509149716 hasConceptScore W2509149716C36394416 @default.
- W2509149716 hasConceptScore W2509149716C43617362 @default.
- W2509149716 hasConceptScore W2509149716C542903549 @default.
- W2509149716 hasConceptScore W2509149716C55493867 @default.
- W2509149716 hasConceptScore W2509149716C71924100 @default.
- W2509149716 hasConceptScore W2509149716C72092618 @default.
- W2509149716 hasConceptScore W2509149716C86803240 @default.
- W2509149716 hasConceptScore W2509149716C89560881 @default.
- W2509149716 hasIssue "1" @default.
- W2509149716 hasLocation W25091497161 @default.
- W2509149716 hasOpenAccess W2509149716 @default.
- W2509149716 hasPrimaryLocation W25091497161 @default.
- W2509149716 hasVolume "38" @default.
- W2509149716 isParatext "false" @default.
- W2509149716 isRetracted "false" @default.
- W2509149716 magId "2509149716" @default.
- W2509149716 workType "article" @default.